CPM
IOVA icon

Connective Portfolio Management’s Iovance Biotherapeutics IOVA Stock Holding History

Connective Portfolio Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-15,000
Closed -$95.9K – 39
2022
Q4 		$95.9K Hold
15,000
– – 0.2% 48
2022
Q3 		$140K Sell
15,000
-15,000
-50% -$173K 0.45% 34
2022
Q2 		$331K Buy
+30,000
New +$393K 0.57% 44

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Connective Portfolio Management's IOVA Position: Q1 2023 in Review

Connective Portfolio Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2023, closing a stake of 15,000 shares — an estimated $95.9K sold.

Connective Portfolio Management first reported a position in IOVA in Q2 2022 and held it in 3 quarters. The position peaked at $331K in Q2 2022. 228 funds tracked by Wall St. Rank hold IOVA as of Q1 2023.

  • Connective Portfolio Management reported no remaining Iovance Biotherapeutics position as of Q1 2023 after selling out during the quarter.
  • Connective Portfolio Management sold 15,000 Iovance Biotherapeutics shares in Q1 2023, an estimated $95.9K.
  • Connective Portfolio Management first reported a position in Iovance Biotherapeutics in Q2 2022 and held it in 3 quarters.
  • Connective Portfolio Management's Iovance Biotherapeutics position peaked at $331K in Q2 2022.
  • 228 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2023.

Based on Connective Portfolio Management's 13F filing for Q1 2023, filed 17 Apr 2023.